这是一项多中心、开放标签、分层、随机研究，旨在评估 durvalumab 或 tremelimumab 单药治疗，或 durvalumab 联合 tremelimumab 或 bevacizumab 用于晚期肝细胞癌的安全性、耐受性、抗肿瘤活性、药物动力学、药效学及免疫原性。

适应症：Hepatocellular Carcinoma

入组条件

Male or female participants
years and older (Japan-20 years and older)
Confirmed hepatocellular carcinoma (HCC) based on histopathological findings from tumor tissues. Advanced HCC with diagnosis confirmed pathologically or with noninvasive methods.
Immunotherapy-naïve
Have either progressed on, are intolerant to, or refused treatment with sorafenib or another approved TKI. For arm 5 only: Have not received any prior systemic therapy for HCC.

Prior exposure to immune-mediated therapy
Hepatic encephalopathy within past 12 months or requirement for medications to prevent or control encephalopathy
Gastrointestinal bleeding (eg, esophageal varices or ulcer bleeding) within 12 months
Ascites requiring non-pharmacologic intervention (eg, paracentesis) to maintain symptomatic control, within 6 months prior to the first scheduled dose.
Main portal vein thrombosis (Vp4) as documented on imaging
Any concurrent chemotherapy, immunotherapy, or biologic or hormonal therapy for cancer treatment
Active or prior documented autoimmune or inflammatory disease with some exceptions
Current or prior use of immunosuppressive medication within 14 days with some exceptions

入组条件维持 ClinicalTrials.gov 原始英文登记资料，实际入组资格以研究团队的正式评估与受试者知情同意书为准。资料来源：ClinicalTrials.gov，每两周自动更新，最后同步：2026年10月8日。

Durvalumab 或 Tremelimumab 单药治疗，或 Durvalumab 联合 Tremelimumab 或 Bevacizumab 用于晚期肝细胞癌的研究